These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 24707943)

  • 1. Phase II study of alemtuzumab-rituximab therapy in previously untreated patients with chronic lymphocytic leukemia: short- and long-term outcomes.
    Frankfurt O; Ma S; Gordon L; Winter JN; Horowitz JM; Rademaker A; Weitner BB; Peterson LC; Altman JK; Tallman MS; Petrich A; Rosen ST
    Leuk Lymphoma; 2015 Feb; 56(2):315-23. PubMed ID: 24707943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101.
    Lin TS; Donohue KA; Byrd JC; Lucas MS; Hoke EE; Bengtson EM; Rai KR; Atkins JN; Link BK; Larson RA
    J Clin Oncol; 2010 Oct; 28(29):4500-6. PubMed ID: 20697069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.
    Zent CS; Wu W; Bowen DA; Hanson CA; Pettinger AM; Shanafelt TD; Kay NE; Leis JF; Call TG
    Leuk Lymphoma; 2013 Mar; 54(3):476-82. PubMed ID: 22853816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908).
    Zent CS; Victoria Wang X; Ketterling RP; Hanson CA; Libby EN; Barrientos JC; Call TG; Chang JE; Liu JJ; Calvo AR; Lazarus HM; Rowe JM; Luger SM; Litzow MR; Tallman MS
    Am J Hematol; 2016 Mar; 91(3):308-12. PubMed ID: 26662208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?
    Van Den Neste E; Letestu R; Aurran-Schleinitz T; Ysebaert L; Feugier P; Leprêtre S; Dartigeas C
    Leuk Lymphoma; 2012 Mar; 53(3):362-70. PubMed ID: 21854093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells.
    Zent CS; Taylor RP; Lindorfer MA; Beum PV; LaPlant B; Wu W; Call TG; Bowen DA; Conte MJ; Frederick LA; Link BK; Blackwell SE; Veeramani S; Baig NA; Viswanatha DS; Weiner GJ; Witzig TE
    Am J Hematol; 2014 Jul; 89(7):757-65. PubMed ID: 24723493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.
    Pettitt AR; Jackson R; Carruthers S; Dodd J; Dodd S; Oates M; Johnson GG; Schuh A; Matutes E; Dearden CE; Catovsky D; Radford JA; Bloor A; Follows GA; Devereux S; Kruger A; Blundell J; Agrawal S; Allsup D; Proctor S; Heartin E; Oscier D; Hamblin TJ; Rawstron A; Hillmen P
    J Clin Oncol; 2012 May; 30(14):1647-55. PubMed ID: 22493413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial.
    Al-Sawaf O; Fischer K; Herling CD; Ritgen M; Böttcher S; Bahlo J; Elter T; Stilgenbauer S; Eichhorst BF; Busch R; Elberskirch U; Abenhardt W; Kneba M; Hallek M; Wendtner CM
    Eur J Haematol; 2017 Mar; 98(3):254-262. PubMed ID: 27862308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Vazquez ER; Spigel DR; Raefsky E; Bearden JD; Saez RA; Greco FA
    Cancer; 2008 Mar; 112(6):1288-95. PubMed ID: 18189296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).
    Nabhan C; Patton D; Gordon LI; Riley MB; Kuzel T; Tallman MS; Rosen ST
    Leuk Lymphoma; 2004 Nov; 45(11):2269-73. PubMed ID: 15512816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Brown JR; Messmer B; Werner L; Davids MS; Mikler E; Supko JG; Fisher DC; LaCasce AS; Armand P; Jacobsen E; Dalton V; Tesar B; Fernandes SM; McDonough S; Ritz J; Rassenti L; Kipps TJ; Neuberg D; Freedman AS
    Haematologica; 2013 Jun; 98(6):964-70. PubMed ID: 23645694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial.
    Elter T; Gercheva-Kyuchukova L; Pylylpenko H; Robak T; Jaksic B; Rekhtman G; Kyrcz-Krzemień S; Vatutin M; Wu J; Sirard C; Hallek M; Engert A
    Lancet Oncol; 2011 Dec; 12(13):1204-13. PubMed ID: 21992852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence.
    Faderl S; Ferrajoli A; Wierda W; O'Brien S; Lerner S; Keating MJ
    Cancer; 2010 May; 116(10):2360-5. PubMed ID: 20225334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.
    Greil R; Obrtlíková P; Smolej L; Kozák T; Steurer M; Andel J; Burgstaller S; Mikušková E; Gercheva L; Nösslinger T; Papajík T; Ladická M; Girschikofsky M; Hrubiško M; Jäger U; Fridrik M; Pecherstorfer M; Králiková E; Burcoveanu C; Spasov E; Petzer A; Mihaylov G; Raynov J; Oexle H; Zabernigg A; Flochová E; Palášthy S; Stehlíková O; Doubek M; Altenhofer P; Pleyer L; Melchardt T; Klingler A; Mayer J; Egle A
    Lancet Haematol; 2016 Jul; 3(7):e317-29. PubMed ID: 27374465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab.
    Zent CS; Call TG; Shanafelt TD; Tschumper RC; Jelinek DF; Bowen DA; Secreto CR; Laplant BR; Kabat BF; Kay NE
    Cancer; 2008 Oct; 113(8):2110-8. PubMed ID: 18759253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903).
    Kempin S; Sun Z; Kay NE; Paietta EM; Mazza JJ; Ketterling RP; Frankfurt O; Claxton DF; Saltzman JN; Srkalovic G; Callander NS; Gross G; Tallman MS
    Acta Haematol; 2019; 142(4):224-232. PubMed ID: 31336367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission rates.
    Zent CS; Call TG; Bowen DA; Conte MJ; LaPlant BR; Witzig TE; Ansell SM; Weiner GJ
    Leuk Lymphoma; 2015; 56(8):2373-8. PubMed ID: 25676035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
    Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
    Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical efficacy and safety of chemoimmunotherapy with rituximab,fludarabine and cyclophosphamide for chronic lymphocytic leukemia].
    Li F; Yi SH; Yu Z; Xing LJ; Xu Y; Qi JY; Zhao YZ; Li ZJ; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2013 May; 34(5):383-8. PubMed ID: 23688746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival.
    Moreton P; Kennedy B; Lucas G; Leach M; Rassam SM; Haynes A; Tighe J; Oscier D; Fegan C; Rawstron A; Hillmen P
    J Clin Oncol; 2005 May; 23(13):2971-9. PubMed ID: 15738539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.